课件：副癌综合征.ppt

Batson:静脉系统,前列腺与低位腰椎之间存在着一条“门样”静脉系统，命名为“椎静脉丛” * * * * MRA:核磁动脉显影；MRV:头颅磁共振静脉成像,MRS:磁共振频谱，检测脑内化学成分（ATP,磷酸肌酸，乳酸素） 放療可能是新診斷多發性腦轉移患者的推薦治療措施，但也可用於孤立性腦轉移患者的治療。為判斷腦轉移瘤的預後，腫瘤放療組織(RTOG)根據預後因素(包括體能狀態、年齡和多發性還是孤立性腦轉移灶)將患者分為三類。研究所用的特定分析方法稱為“回歸分割分析-RPA”，因此將基於RPA的分類稱為腦轉移瘤的RTOG RPA分類。表3列舉了三個RPA分類及其相關的中位生存期。 脑转移癌的治疗较复杂，要根据转移瘤原发部位、组织学来源、患者一般情况、脑转移灶数目、 原发灶控制情况来判定。常使用综合治疗的方法。 * * - This phase ll study evaluated the safety and efficacy of the combination of ERBITUX and FOLFOX-4 as first-line treatment for patients with mCRC. 1. Cervantes A, Casado E, Van Cutsem E et al. Eur J Cancer 2005;Supplement 3:Abstract 642. Updated information presented at ECCO 2005 * * - In this multicenter, open-label, phase II study, patients with metastatic or recurrent CRC received first-line treatment with ERBITUX (400 mg/m2 week 1 and 250 mg/m2 weekly thereafter) plus FOLFOX-4 (every 2 weeks: oxaliplatin 85 mg/m2, day 1; FA 200 mg/m2 2-h infusion and 5-FU 400 mg/m2 i.v. bolus followed by 600 mg/m2 continuous infusion for 22-h, days 1 and 2). - Treatment was continued until disease progression or unacceptable toxicity. 1. Cervantes A, Casado E, Van Cutsem E et al. Eur J Cancer 2005;Supplement 3:Abstract 642. Updated information presented at ECCO 2005 * * - Of the 60 enrolled patients, 46 (77%) were male and the median age was 44.5 years. - The majority of patients were Chinese. - The median Karnofsky performance status was 90%. - The majority of patients (93%) had stage IV disease. Among these patients, 85% had distant metastasis. - The median duration of disease at time of enrolment on the study was 24.2 months. 1. Chan AT, Hsu MM, Goh BC, et al. J Clin Oncol 2005;23:3568-3576 * * - The primary endpoint for the study was the best confirmed overall response. - The secondary endpoints were: -- progression-free survival -- duration of response -- survival time -- safety. 1. Cervantes A, Casado E, Van Cutsem E et al. Eur J Cancer 2005;Supplement 3:Abstract 642. Updated information presented at ECCO 200